Insider Selling: Healthequity Inc (NASDAQ:HQY) Director Sells 700 Shares of Stock

Healthequity Inc (NASDAQ:HQY) Director Frank Medici sold 700 shares of the stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $51.05, for a total value of $35,735.00. Following the sale, the director now directly owns 6,381 shares of the company’s stock, valued at $325,750.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Frank Medici also recently made the following trade(s):

  • On Wednesday, November 29th, Frank Medici sold 13,000 shares of Healthequity stock. The shares were sold at an average price of $52.14, for a total value of $677,820.00.
  • On Friday, November 24th, Frank Medici sold 7,540 shares of Healthequity stock. The stock was sold at an average price of $51.42, for a total value of $387,706.80.
  • On Tuesday, November 21st, Frank Medici sold 58,481 shares of Healthequity stock. The stock was sold at an average price of $51.25, for a total value of $2,997,151.25.
  • On Friday, November 3rd, Frank Medici sold 32,404 shares of Healthequity stock. The stock was sold at an average price of $51.09, for a total value of $1,655,520.36.
  • On Monday, November 6th, Frank Medici sold 419,504 shares of Healthequity stock. The stock was sold at an average price of $52.97, for a total value of $22,221,126.88.
  • On Tuesday, October 24th, Frank Medici sold 7,900 shares of Healthequity stock. The stock was sold at an average price of $51.11, for a total value of $403,769.00.
  • On Monday, October 9th, Frank Medici sold 316,644 shares of Healthequity stock. The stock was sold at an average price of $51.96, for a total value of $16,452,822.24.

Shares of Healthequity Inc (NASDAQ HQY) traded down $0.41 on Monday, hitting $51.46. The company’s stock had a trading volume of 380,900 shares, compared to its average volume of 522,815. Healthequity Inc has a one year low of $37.62 and a one year high of $55.31. The firm has a market cap of $3,112.75, a price-to-earnings ratio of 81.68, a price-to-earnings-growth ratio of 2.26 and a beta of 1.74.

Healthequity (NASDAQ:HQY) last announced its earnings results on Tuesday, September 5th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.14 by $0.13. Healthequity had a return on equity of 13.93% and a net margin of 20.27%. The company had revenue of $56.90 million for the quarter, compared to analyst estimates of $55.66 million. During the same period in the prior year, the company posted $0.16 EPS. Healthequity’s quarterly revenue was up 28.7% on a year-over-year basis. research analysts forecast that Healthequity Inc will post 0.7 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Amussen Hunsaker Associates LLC grew its stake in shares of Healthequity by 1.9% in the third quarter. Amussen Hunsaker Associates LLC now owns 237,239 shares of the company’s stock worth $12,000,000 after purchasing an additional 4,493 shares in the last quarter. Piedmont Investment Advisors LLC grew its stake in shares of Healthequity by 15.9% in the third quarter. Piedmont Investment Advisors LLC now owns 11,105 shares of the company’s stock worth $562,000 after purchasing an additional 1,520 shares in the last quarter. California Public Employees Retirement System grew its stake in shares of Healthequity by 4.0% in the third quarter. California Public Employees Retirement System now owns 95,859 shares of the company’s stock worth $4,849,000 after purchasing an additional 3,659 shares in the last quarter. Crestline Management LP bought a new position in shares of Healthequity in the third quarter worth $1,543,000. Finally, Zions Bancorporation bought a new position in shares of Healthequity in the third quarter worth $119,000. Hedge funds and other institutional investors own 98.60% of the company’s stock.

Several analysts have commented on the company. Zacks Investment Research upgraded Healthequity from a “hold” rating to a “buy” rating and set a $60.00 price target for the company in a report on Wednesday, November 8th. Oppenheimer restated a “buy” rating and issued a $61.00 price target on shares of Healthequity in a report on Wednesday, September 6th. Cantor Fitzgerald restated a “buy” rating and issued a $56.00 price target on shares of Healthequity in a report on Tuesday, September 5th. BidaskClub raised Healthequity from a “sell” rating to a “hold” rating in a research note on Thursday, September 28th. Finally, Robert W. Baird reaffirmed a “hold” rating on shares of Healthequity in a research note on Thursday, September 21st. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $57.50.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Week Herald and is the sole property of of Week Herald. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://weekherald.com/2017/12/04/healthequity-inc-hqy-director-frank-medici-sells-700-shares-of-stock.html.

About Healthequity

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Insider Buying and Selling by Quarter for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply